Scrip“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
In VivoBy 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030
In VivoAmongst a crowded research space, Skye Bioscience, Inc. aims to differentiate itself with a longer-term approach to combatting obesity. Its lead asset, nimacimab, functions as a negative allosteric
ScripRadionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b